Japan Earnings Highlights: Takeda, Astellas And Eisai
This article was originally published in PharmAsia News
Executive Summary
Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.
You may also be interested in...
Takeda Has Another Shot Remaining With Orteronel In Prostate Cancer
Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.
European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.
Obesity Drugs Could Get Lift From Part D Legislation, AMA Policy
Two events lead the way to greater coverage and reimbursement for obesity drugs: a bipartisan, bicameral bill that would remove Medicare Part D’s ban on covering obesity drugs and AMA’s recognition of obesity as a disease.